Altogether, these data revealed that the expression of Igfbp1 and Igfbp2 in other mouse models and patients with obesity-associated steatosis and IR is generally either unchanged or downregulated as in LPTENKO mice (Figure 4, Figure S4 and Table S7), thus suggesting that they may not be relevant in mediating the beneficial metabolic effects observed in LPTENKO mice. This evidence concerns the gene IGFBP2 and obesity disorder.